Novartis returns to appellate court, requesting rehearing and reversal in Gilenya patent case
Novartis may have suffered a setback in court over its blockbuster neuroscience drug Gilenya, but the pharma giant isn’t done fighting for it.
A month …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
